Bacopa monnieri ： Memory Loss
A エビデンス 複数の大規模臨床試験が一貫して有意な効果を示しています。Multiple systematic reviews consistently report small-to-moderate improvements in memory recall and processing speed after 8-12 weeks of Bacopa use. A network meta-analysis found high-dose Bacopa (600+ mg/day) significantly improved working and short-term memory.
<\/script>\n`;
},
get iframeSnippet() {
const domain = 'braincited.com';
const params = 'ingredient\u003Dbacopa\u002Dmonnieri\u0026condition\u003Dmemory\u002Dloss';
return ``;
},
get activeSnippet() {
return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet;
},
copySnippet() {
navigator.clipboard.writeText(this.activeSnippet).then(() => {
this.copied = true;
setTimeout(() => { this.copied = false; }, 2000);
});
}
}"
@keydown.escape.window="open = false"
@click.outside="open = false">
A
結論
Multiple systematic reviews consistently report small-to-moderate improvements in memory recall and processing speed after 8-12 weeks of Bacopa use. A network meta-analysis found high-dose Bacopa (600+ mg/day) significantly improved working and short-term memory.
Key Study Findings
Systematic Review
Cholinesterase Inhibitors from Plants and Their Potential in Alzheimer's Treatment: Systematic Review.
Dose: None
vs: None
Outcome: Cholinesterase inhibition and cognitive improvement
効果: None
None
対象集団: In vivo animal models of AD
Other
Differential Alterations in the Expression of AMPA Receptor and Its Trafficking Proteins in the Hippocampus …
Dose: 200 mg/kg body weight
vs: Rotenone-PD mice without BME
Outcome: Recognition memory and AMPA receptor expression
効果: None
None
対象集団: Rotenone-induced Parkinson's disease mouse model
Review
Comprehensive Insights into Pathophysiology of Alzheimer's Disease: Herbal Approaches for Mitigating Neurodegeneration.
Dose: None
vs: None
Outcome: Cognitive decline
効果: None
None
対象集団: Alzheimer's disease patients
Other
Exploring the immunomodulatory potential of Brahmi (Bacopa monnieri) in the treatment of invasive ductal carcinoma.
Dose: Bacopa monnieri (Brahmi)
vs: None
Outcome: Immunomodulatory effects in breast cancer
効果: None
None
対象集団: Retracted publication - invasive ductal carcinoma
In Vitro
Bacopa monnieri: A promising herbal approach for neurodegenerative disease treatment supported by in silico and …
Dose: Bacopa monnieri phytocompounds
vs: Standard AChE inhibitors
Outcome: AChE inhibition and neuroprotection
効果: None
None
対象集団: In silico/in vitro NDD study
In Vitro
Bacopa monnieri reduces Tau aggregation and Tau-mediated toxicity in cells.
Dose: None
vs: None
Outcome: oxidative stress markers
効果: None
None
対象集団: None
Key Statistics
22
研究数
1800
参加者数
↑
Positive
A
グレード
Referenced Papers
Brain sciences
2025
14 件の引用
Molecular neurobiology
2025
3 件の引用
Current Alzheimer research
2024
10 件の引用
Medical oncology (Northwood, …
2024
2 件の引用
Heliyon
2023
20 件の引用
International journal of …
2023
13 件の引用
The Senior care …
2021
2 件の引用
Scientific reports
2021
1 件の引用
Brain sciences
2020
72 件の引用
Annals of Indian …
2020
17 件の引用
Drug target insights
2019
103 件の引用
Current neuropharmacology
2019
53 件の引用
Epilepsy & behavior …
2018
28 件の引用
Journal of ethnopharmacology
2017
98 件の引用
PloS one
2015
51 件の引用
Evidence-based complementary and …
2015
14 件の引用
Neurochemical research
2012
85 件の引用
Recent patents on …
2011
132 件の引用
Dosage & Usage
mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units
一般的な使用量
- general:
- 300-600 mg/day standardized to 50% bacosides
- memorysupport:
- 300 mg/day for minimum 8-12 weeks
上限量： Not established; well-tolerated up to 600 mg/day in trials
研究で検討された用量
| 用量 | 期間 | 効果 | N |
|---|---|---|---|
| None | -- | Positive | -- |
| 200 mg/kg body weight | -- | Positive | -- |
| None | -- | Mixed | -- |
| Bacopa monnieri (Brahmi) | -- | Positive | -- |
| Bacopa monnieri phytocompounds | -- | Positive | -- |
| None | -- | Mixed | -- |
| None | -- | Positive | -- |
| None | 72 weeks | Positive | -- |
推奨摂取タイミング： With meals; effects require 8-12 weeks of consistent use
Safety & Side Effects
報告されている副作用
- ⚠ Gastrointestinal discomfort (nausea, cramping, diarrhea)
- ⚠ Dry mouth
- ⚠ Fatigue in some individuals
- ⚠ Mild sedation at higher doses
既知の相互作用
- ● Thyroid medications (may increase thyroid hormone levels)
- ● Anticholinergic drugs (opposes cholinergic enhancement)
- ● Sedative medications (additive CNS depression)
- ● Calcium channel blockers (may enhance blood pressure lowering)
耐容上限摂取量： Not established; well-tolerated up to 600 mg/day in trials
サプリメントの摂取を開始する前に、必ず医療専門家にご相談ください。
Frequently Asked Questions
Does Bacopa monnieri help with Memory Loss?
Based on 22 studies with 1,800 participants, there is strong evidence from multiple clinical trials that Bacopa monnieri may support Memory Loss management. Our evidence grade is A (Strong Evidence).
How much Bacopa monnieri should I take for Memory Loss?
Studies have used various dosages. A commonly studied range is 300-600 mg/day standardized to 50% bacosides. Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of Bacopa monnieri?
Reported side effects may include Gastrointestinal discomfort (nausea, cramping, diarrhea), Dry mouth, Fatigue in some individuals, Mild sedation at higher doses. Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for Bacopa monnieri and Memory Loss?
We rate the evidence as Grade A (Strong Evidence). This rating is based on 22 peer-reviewed studies with 1,800 total participants. The overall direction of effect is positive.
Related Evidence
に関する他の成分： Memory Loss
Bacopa monnieri 他の症状・状態について
References
- [1] Maryam N ALNasser et al.. Brain Sci. 2025. Cholinesterase Inhibitors from Plants and Their Potential in Alzheimer's Treatment: Systematic Review. doi:10.3390/brainsci15020215 PubMed
- [2] Vartika Gupta et al.. Mol Neurobiol. 2025. Differential Alterations in the Expression of AMPA Receptor and Its Trafficking Proteins in the Hippocampus Are Associated with Recognition Memory … doi:10.1007/s12035-024-04392-1 PubMed
- [3] Debasis Sen et al.. Curr Alzheimer Res. 2024. Comprehensive Insights into Pathophysiology of Alzheimer's Disease: Herbal Approaches for Mitigating Neurodegeneration. doi:10.2174/0115672050309057240404075003 PubMed
- [4] Sohini Roy et al.. Med Oncol. 2024. Exploring the immunomodulatory potential of Brahmi (Bacopa monnieri) in the treatment of invasive ductal carcinoma. doi:10.1007/s12032-024-02365-x PubMed
- [5] Shehla Shoukat et al.. Heliyon. 2023. Bacopa monnieri: A promising herbal approach for neurodegenerative disease treatment supported by in silico and in vitro research. doi:10.1016/j.heliyon.2023.e21161 PubMed
- [6] Tushar Dubey et al.. Int J Biol Macromol. 2023. Bacopa monnieri reduces Tau aggregation and Tau-mediated toxicity in cells. doi:10.1016/j.ijbiomac.2023.123171 PubMed
- [7] Brittany R Block et al.. Sr Care Pharm. 2021. Online Promotion of "Brain Health" Supplements. doi:10.4140/TCP.n.2021.489 PubMed
- [8] James M Brimson et al.. Sci Rep. 2021. The effectiveness of Bacopa monnieri (Linn.) Wettst. as a nootropic, neuroprotective, or antidepressant supplement: analysis of the available clinical data. doi:10.1038/s41598-020-80045-2 PubMed
- [9] Jogender Mehla et al.. Brain Sci. 2020. Indian Medicinal Herbs and Formulations for Alzheimer's Disease, from Traditional Knowledge to Scientific Assessment. doi:10.3390/brainsci10120964 PubMed
- [10] Sudesh Prabhakar et al.. Ann Indian Acad Neurol. 2020. Efficacy of Bacopa Monnieri (Brahmi) and Donepezil in Alzheimer's Disease and Mild Cognitive Impairment: A Randomized Double-Blind Parallel Phase 2b … doi:10.4103/aian.AIAN_610_19 PubMed
- [11] Aimi Syamima Abdul Manap et al.. Drug Target Insights. 2019. Bacopa monnieri, a Neuroprotective Lead in Alzheimer Disease: A Review on Its Properties, Mechanisms of Action, and Preclinical and Clinical … doi:10.1177/1177392819866412 PubMed
- [12] Vini C Sekhar et al.. Curr Neuropharmacol. 2019. Insights Into the Molecular Aspects of Neuroprotective Bacoside A and Bacopaside I. doi:10.2174/1570159X16666180419123022 PubMed
- [13] Amrita Mishra et al.. Epilepsy Behav. 2018. Effect of traditional medicine brahmi vati and bacoside A-rich fraction of Bacopa monnieri on acute pentylenetetrzole-induced seizures, amphetamine-induced model of … doi:10.1016/j.yebeh.2017.12.040 PubMed
- [14] Michelle D Nemetchek et al.. J Ethnopharmacol. 2017. The Ayurvedic plant Bacopa monnieri inhibits inflammatory pathways in the brain. doi:10.1016/j.jep.2016.07.073 PubMed
- [15] Surya P Pandey et al.. PLoS One. 2015. Alterations in Hippocampal Oxidative Stress, Expression of AMPA Receptor GluR2 Subunit and Associated Spatial Memory Loss by Bacopa monnieri Extract … doi:10.1371/journal.pone.0131862 PubMed
- [16] Anupama Rani et al.. Evid Based Complement Alternat Med. 2015. A Special Extract of Bacopa monnieri (CDRI-08)-Restored Memory in CoCl2-Hypoxia Mimetic Mice Is Associated with Upregulation of Fmr-1 Gene Expression … doi:10.1155/2015/347978 PubMed
- [17] Neetu Saini et al.. Neurochem Res. 2012. Neuroprotective effects of Bacopa monnieri in experimental model of dementia. doi:10.1007/s11064-012-0811-4 PubMed
- [18] G K Shinomol et al.. Recent Pat Endocr Metab Immune Drug Discov. 2011. Exploring the Role of “Brahmi” (Bacopa monnieri and Centella asiatica) in Brain Function and Therapy. doi:10.2174/187221411794351833 PubMed
FDAに関する免責事項: これらの記述は米国食品医薬品局（FDA）による評価を受けていません。本ウェブサイトの製品および情報は、疾病の診断、治療、治癒、または予防を目的としたものではありません。表示されているエビデンスグレードは、公開された査読済み研究の分析に基づいており、医療上の助言を構成するものではありません。サプリメントの摂取を開始する前に、必ず医療専門家にご相談ください。